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Background: Intratumoural heterogeneity has been demonstrated to be a strong indicator of malignant
transformation. Our study was to investigate pretreatment 18 F-FDG parameters, including 18 F-FDG based
heterogeneity for predicting survival in patients with locally advanced nasopharyngeal carcinoma (NPC).
Methods: Forty newly diagnosed, biopsy-proven locally advanced NPC patients who underwent 18 F-FDG PET/CT
were retrospectively included. The following PET parameters were assessed: maximum and mean standardised
uptake value (SUVmax and SUVmean), metabolic tumour volume (MTV), total lesion glycolysis (TLG) and intratumoral
heterogeneity index (HI). The previous parameters were recorded both for the primary tumor (-T) and neck lymph
nodes (-N). The following endpoints were evaluated: local control (LC), progression-free survival (PFS) and overall
survival (OS). The survival analyses were performed using the Kaplan–Meier method. Univariate analysis was performed
using the log-rank test.
Results: Patients with a lower HI-T, SUVmax-T, SUVmean-T and TLG-T had significantly better 2-year LC. In predicting
PFS, we found that both lower HI-T and HI-N had significantly better prognosis. However, the OS was only statistically
associated with HI-T.
Conclusion: 18 F-FDG based heterogeneity appears to be an potential predicator of patient survival after treatment.
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Nasopharyngeal carcinoma (NPC) is unique in terms of
epidemiology, pathogenesis, and physical history com-
pared to the anatomically adjacent cancers of the head
and neck area. It is etiologically associated with the
Epstein-Barr virus, and shows an endemic distribution:
incidence rates are highest in South-Eastern Asia, includ-
ing Malaysia, Indonesia, Singapore and South-Eastern* Correspondence: profzhangyj@163.com; hucsu62@yahoo.com
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unless otherwise stated.China, and as such is the sixth most common cancer
among males in the region [1].
NPC is a very radiosensitive tumor [2]; in addition, con-
current chemoradiation (CCRT) and induction chemo-
therapy (Chemo) have been shown to improve tumor
control and survival in patients with locally advanced
NPC [3,4]. However, some patients may still develop
locoregional and distant failure, thus requiring salvage or
palliative therapy [5-7]. Although traditional prognostic
factors may provide some useful clinical information, they
cannot predict treatment outcome reliably. Therefore,
substantial research efforts have focused on the identifica-
tion of novel prognostic factors to further stratify risk
groups with the goal of developing individualized treat-
ment strategies for these patients.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient demographics and clinical characteristics
Demographic or clinical No. of
patients
%
Characteristic (n = 40)
Age Median 52.5
Range 28 ~ 70
Gender Male 29 72.5
Female 11 27.5
Histology Squamous cell carcinoma 8 20.0
Non-keratinizing carcinoma 32 80.0
T stage 3 25 62.5
4 15 37.5




Treatment modality Chemo + RT 21 52.5
Chemo + CCRT 19 47.5
Chemo = induction chemotherapy, RT = radiotherapy, CCRT = concurrent
chemoradiotherapy.
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has been used in patients with NPC for the initial diagno-
sis and staging workup [8-10]. Several investigators have
examined the value of 18 F-FDG PET functional parame-
ters, such as maximum standard uptake value (SUVmax)
and mean SUV (SUVmean) for predicting the prognosis
of NPC [11-13]. Recently, other semi-quantitative parame-
ters, for instance, metabolic tumor volume (MTV) and
total lesion glycolysis (TLG) are becoming a topic of inter-
est in cancer research. Some studies showed that MTV
and TLG are important independent risk factors in pri-
mary NPC patients [14-17]. However, these parameters
have not been sufficiently evaluated because they yielded
conflicting results.
Intratumoural heterogeneity has been demonstrated to
be a strong indicator of malignant transformation, and
one might hypothesize that the texture of intratumoural
tracer uptake on PET may represent a likewise useful
parameter [18]. Therefore, our study was aimed to inves-
tigate 18 F-FDG parameters, including 18 F-FDG based




Forty consecutive patients with newly diagnosed (the
interval between date of diagnose and FDG scan date
was about 1 week), biopsy-proven locally advanced NPC
referred to our center between November 2006 and
December 2011 for whole-body 18 F-FDG PET/CT were
retrospectively included. Patients with metastatic disease
at presentation (M1 stage), with other malignancies, or
who had been previously treated at other institutions
were excluded. All patients were staged according to
2010 American Joint Committee on Cancer staging
system.
Pretreatment evaluation was composed of whole-body
18 F-FDG PET/CT, and routine procedures including
complete medical history, physical examination, indirect
or fiberoptic endoscopic examination of nasopharynx,
biopsy of the neoplasm in nasopharynx, head and neck
Magnetic Resonance Imaging (MRI) scans. These exami-
nations were performed within 2 weeks before treat-
ment. Our study need not get an approval from the
review board because it was only a retrospective study.
However, PET/CT is not covered by insurance in China,
and informed written consent was obtained from our
patients before examination.
PET/CT imaging
18 F-FDG was produced automatically by cyclotron
(Siemens CTI RDS Eclips ST, Knoxville, Tennessee,
USA) using Explora FDG4 module in our center. Radio-
chemical purity was over 95%.Before the 18 F-FDG PET/CT, all the patients were re-
quested to fast at least 4 h. At the time of the tracer injec-
tion (dosage: 7.4 MBq/kg), the patients presented blood
glucose level under 10 mmol/L. Before and after injection,
patients were kept lying comfortably in a quiet, dimly lit
room. Scanning was initiated 1 h after administration
of the tracer. The images were obtained on a Siemens
biograph 16HR PET/CT scanner (Knoxville, Tennessee,
USA). The transaxial intrinsic spatial resolution was
4.1 mm (full-width at half-maximum) in the center of
the field of view. The data acquisition procedure was as
follows: CT scanning was first performed, from the
proximal thighs to head, with 120 kV, 80 ~ 250 mA,
pitch 3.6, rotation time 0.5. Immediately after CT scan-
ning, a PET emission scan that covered the identical
transverse field of view was obtained. Acquisition time
was 2 ~ 3 min per table position. PET image data sets
were reconstructed iteratively by applying the CT data
for attenuation correction, and coregistered images
were displayed on a workstation.
Imaging interpretation
A multimodality computer platform (Syngo, Siemens,
Knoxville, Tennessee, USA) was used for image review
and manipulation. Two experienced nuclear medicine
physician evaluated the images independently. The re-
viewers reached a consensus in cases of discrepancy.
Quantification of glucose metabolic activity was ob-
tained using the SUV normalized to body weight. The
SUVmax and SUVmean for primary tumor (SUVmax-T,
SUVmean-T) and neck lymph nodes (SUVmax-N,




2-year rate (%) p 2-year rate (%) p 2-year rate (%) p
Age (year)
<53 20 95.0 0.782 80.0 0.634 95.0 0.776
≥53 20 94.7 70.0 95.0
Gender
Male 29 100.0 0.016 72.4 0.868 96.6 0.644
Female 11 81.8 81.8 90.9
Histology
Squamous cell carcinoma 8 87.5 0.685 75.0 0.863 87.5 0.212
Non-keratinizing carcinoma 32 96.8 75.0 96.9
T stage
3 26 96.2 0.276 73.1 0.592 96.2 0.721
4 14 92.3 78.6 92.9
N stage
0-2 31 93.4 0.239 77.4 0.811 93.5 0.734
3 9 100.0 66.7 100.0
Treatment modality
Chemo + RT 21 95.0 0.086 76.2 0.594 95.2 0.968
Chemo + CCRT 19 94.7 73.7 94.7
HI-T
<2.9 23 100.0 0.028 100.0 <0.0001 100.0 0.022
≥2.9 17 87.8 41.2 88.2
SUVmax-T
<15.6 29 100.0 0.001 72.4 0.933 96.6 0.641
≥15.6 11 81.8 81.8 90.9
SUVmean-T
<4.7 23 100.0 0.006 69.6 0.929 95.7 0.942
≥4.7 17 88.2 82.4 94.1
MTV-T (ml)
<28.9 13 100.0 0.111 76.9 0.684 100.0 0.848
≥28.9 27 92.4 74.1 92.6
TLG-T (g)
<249.1 27 100.0 0.006 74.1 0.976 96.3 0.898
≥249.1 13 84.6 76.9 92.3
HI-N
<2.3 26 92.3 0.500 84.6 0.009 96.2 0.411
≥2.3 14 100.0 57.1 92.9
SUVmax-N
<7.6 20 95.0 0.692 75.0 0.672 95.0 0.891
≥7.6 20 94.7 75.0 95.0
SUVmean-N
<5.4 30 93.3 0.232 76.7 0.634 96.7 0.088
≥5.4 10 100.0 70.0 90.0
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Table 2 General characteristic and results of the univariate analysis of risk factors associated with LC, PFS and OS
(Continued)
MTV-N (ml)
<11.1 28 92.9 0.125 78.6 0.907 96.4 0.270
≥11.1 12 100.0 66.7 91.7
TLG-N (g)
<80.4 32 93.6 0.235 75.0 0.429 93.8 0.770
≥80.4 8 100.0 75.0 100.0
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bolic tumor volume (MTV) was also recorded. The
boundaries were drawn large enough to include the pri-
mary tumor within the nasopharynx or neck lymph
nodes in the axial, coronal, and sagittal PET images. To
define the contouring margins around the target, we
used an SUV of 2.5. The contour around the target le-
sion inside the boundaries was automatically produced
and the voxels presenting SUV intensity of greater than
2.5 within the contouring margin were incorporated to
define the MTV. The TLG was calculated according to
the following formula: TLG = SUVmean ×MTV. A quan-
titative measure of intratumoral heterogeneity, hetero-
geneity index (HI) was obtained by dividing SUVmax by
SUVmean for primary lesion and nodal disease [18,19].
Treatment and follow-up
Primary curative treatment consisted of Chemo + radio-
therapy (RT) or Chemo + CCRT, according to the tumor
stage and other clinical characteristics. As for RT, all pa-
tients received Intensity-Modulated Radiation Therapy
(IMRT) for a cumulative dose of 70.4Gy in 32 fractions.
We used TPF protocol for Chemo, which consisted of
docetaxel 75 mg/m2 IV on day 1, cisplatin 75 mg/m2 IV
on day 1, and 5-Fu 500 mg/m2/d continuously IV on 1-5
day. With respect to CCRT, cisplatin 40 mg/m2 was used
IV weekly during radiation. The treatment protocal was
approved by the Nasopharygneal carcinoma multidiscip-
linary team in our hospital after discussion.
Patients were followed every 3 months in the first to
second year, then every 6 months in the third to fifth
year and once a year thereafter. In each visit, medical
history, physical examination and nasopharyngoscopy
were performed. Nasopharyngeal MRI was performed
3 months and 1 year after completion of radiotherapy,
and every 6 months in the second to fifth year, and then
yearly thereafter. The following tests were done at least
every year: chest CT or X-ray, abdominal sonography,
and bone scan when clinically indicated.
Distant metastasis was proven by clinical and radiologic
evidence, and pathologic evidence if possible. For those
without pathologic evidence and obvious clinical symp-
toms, radiologic evidence would play a more importantrole. If radiologic evidence was not strong enough to
prove metastatic disease at primary diagnosis, then a
metastatic lesion might be proven by its enlargement or
regression during or after chemotherapy.
Statistical analysis
We identified progression disease (PD) according to
RECIST1.1. The following endpoints were evaluated:
local control (LC), progression-free survival (PFS) and
overall survival (OS). The PFS duration was measured
from the date of first scan to the date of disease progres-
sion or was censored at the last follow-up date. Survival
was defined as the time between the date of diagnosis
and the date of death or last follow-up. The optimal
SUVmax cut-off value for each endpoint, which showed
the best trade-off between sensitivity and specificity, was
determined by receiver operating characteristic (ROC)
analysis following the method of Metz [20]. The survival
analyses were performed using the Kaplan–Meier
method. Univariate analysis was performed using the
log-rank test. Data was analyzed by SPSS 13.0 software.
All analyses were two-sided. A p value less than 0.05
was taken to indicate a significant difference.
Results
Patient characteristics and treatment outcome
The demographics and clinical characteristics of the pa-
tients were showed in Table 1. In our study, the median
follow-up period was 30.5 months (range from 24.0- to
68.0 months). At the end of follow-up, among the 40 pa-
tients, 35 patients were alive and 5 patients had died, 5
experienced local recurrences and distant metastases
happened in 10 patients. Distant metastasis was the
main treatment failure, and the common sites of distant
failure were liver, lung and bone.
Univariate analysis
Univariate analysis of prognostic factors for 2-year LC, PFS
and OS were summarized in Table 2. The optimal cut-off
value of HI-T, SUVmax-T, SUVmean-T, MTV-T, TLG-T,
HI-N, SUVmax-N, SUVmean-N, MTV-N and TLG-N,
determined by ROC analysis, were 2.9, 15.6, 4.7, 28.9 ml,
249.1 g, 2.3, 7.6, 5.4, 11.1 ml and 80.4 g, respectively.
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prognostic factors in the entire study cohort. The re-
sults showed that only gender was significantly associ-
ated with LC. With regard to the PET parameters,
patients with a lower HI-T, SUVmax-T, SUVmean-TFigure 1 The Kaplan–Meier curves for the LC of locally advanced NPC
p < 0.05).and TLG-T had significantly better 2-year LC (Figure 1).
In predicting PFS, we found that both lower HI-T and
HI-N had significantly better prognosis (Figure 2).
However, the OS was only statistically associated with
HI-T (Figure 3).patients (A Gender; B HI-T; C SUVmax-T; D SUVmean-T; E TLG-T;
Figure 2 The Kaplan–Meier curves for the PFS of locally advanced NPC patients (A HI-T;B HI-N; p < 0.05).
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Prognostic factors for malignant tumors have always
been attracting a lot of attention, because such a result
could allow therapy to be tailored to the characteristics
of an individual patient [21,22]. However, modern cancer
care is critically dependent on imaging technologies. As
a molecular imaging technology, PET can provide infor-
mation about the functional or metabolic characteristics
of malignancies, tumor stage and therapeutical response,
and tumor recurrence; whereas conventional imaging
technologies predominantly assess anatomical or mor-
phological features of the tumor including its size, dens-
ity, shape and so on [23,24]. There have been researches
indicating that 18 F-FDG PET may non-invasively predict
tumor response to treatment and reflect biologic aggres-
siveness of tumor such as cell viability, proliferativeFigure 3 The Kaplan–Meier curve of different HI-T group for the OS oactivity, hypoxia, low apoptosis rate, and P53 over-
expression in head and neck tumors [25].
Recently, PET-derived parameters, such as the SUV
and MTV, have shown potential prognostic value for
primary NPC in several reports [11-17]. But most of
them only analyzed the predictive value of no more than
two PET parameters, and always focused on traditional
parameters. Additionally, the results were varied and
controversial. Among them, the SUV was the most
widely used predicator. Several investigations suggested
SUV could be valuable in prognosis [11-14,17] while
some studies showed its uselessness [15,16]. Besides,
most previous studies failed to point out the definite pat-
tern of treatment failure (for instance, local recurrence
or distant metastasis) which PET parameters may pre-
dict, so the conclusions were not able to guide whichf locally advanced NPC patients ( p = 0.022).
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boost dose or chemotherapy, should be used in patients
of high-risk predicted by 18 F-FDG PET.
In our study, SUVmax-T and SUVmean-T was associ-
ated with LC with a cut-off value of 15.6 and 4.7, which
was higher than previous studies (SUVmax ranged from
6.48 to 12.0) [11-14,17]. In view of our enrolled patients,
who were all locally advanced NPC, we arbitarily consid-
ered that the higher SUVmax was attributed to higer
staging (T3-4) with more aggressive potential.
Recent investigators demonstrated that MTV and TLG
were better than SUV alone for predicting prognosis
[14-17]. Furthemore, TLG would be expected to provide a
better prognostic stratification than either MTV or SUV
because it integrates both anatomic (tumour volume) and
biological data (glucose metabolism) theoretically. Never-
theless, our study showed TLG was only valuable in LC;
Therefore, whether TLG was better than SUV or MTV in
predicting prognosis of NPC was still unclear.
It is recognized that malignant tumors exhibit intratu-
moral biological heterogeneity associated with cellular and
molecular characteristics such as cellular proliferation, ne-
crosis, fibrosis, differences in blood flow and angiogenesis,
cellular metabolism, hypoxia and expression of specific
receptors, some of which may be evident on histological
analysis. Similarly, heterogeneity of 18 F-FDG uptake
within tumors has been attributed to a number of factors
including cellularity, proliferation, angiogenesis, necrosis
and hypoxia, factors that independently have been associ-
ated with more aggressive behaviour, poorer response to
treatment and worse prognosis [26].
Intratumoral heterogeneity in 18 F-FDG PET images has
been evaluated using textural analysis [27-29], the co-
efficient of variance (COV) [30], cumulative SUV-volume
histograms (CSH) [31], the area under the CSH (AUC–
CSH) [30,32] and fractal analysis [33]. However, the
methods mentioned above were too complex to be used
in clinical application. Recently, a feasible quantitative
measure of heterogeneity, HI, has been successfully ap-
plied [18,19]. HI was obtained by dividing SUVmax by
SUVmean, which could be easily measured in practice. In
our study, we found that both HI-T and HI-N could be
potentially used in predicting survivals. The consequences
indicated that we should pay more attention to the tumor
with greater heterogeneity.
The Radiation Therapy Oncology Group has conducted
a study of concurrent chemoradiotherapy followed by ad-
juvant chemotherapy with bevacizumab (RTOG 0615).
The results indicated that the therapy is feasible and may
delay the progression of subclinical distant disease [34].
Another phase II clinical trial of cetuximab with concur-
rent chemoradiotherapy in locoregionally advanced NPC
also showed that the strategy is feasible and the prelimin-
ary rate was favorable comparing with historic data [35]. Itis our opinion that more aggressive systematic treatment
may be considered in the patients with high risk of
treatment failure, which could be predicted by HI-T of
FDG PET.
Of course, the present study had several limitations.
The first was the retrospective nature of the study.
Another limitation was the relatively small number of
patients, which might have led to the selection bias. The
third and the largest drawback was the low number of
events.
Conclusion
Our preliminary study demonstrated that pretreatment
18 F-FDG based heterogeneity appears to be an potential
predicator of locally advanced NPC patient for disease
progression and overall survival after treatment. These
findings provide additional evidence supporting the use
of 18 F-FDG PET in the clinical management of patients
with NPC.
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